Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Erlotinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 402.00 | 350.25 | 1.1478 | 1.3735 |
| SK-BR-3 | Erlotinib | 1 | uM | 9 | 312.50 | 200.50 | 368.00 | 350.25 | 1.0507 | 1.1267 |
| SK-BR-3 | Lapatinib | 10 | uM | 9 | 312.50 | 200.50 | 153.00 | 350.25 | 0.4368 | -0.2854 |
| SK-BR-3 | Linsitinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 344.00 | 350.25 | 0.9822 | 0.9558 |
| SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 312.50 | 200.50 | 504.00 | 350.25 | 1.4390 | 2.1436 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 363.00 | 350.25 | 1.0364 | 1.0909 |
| SK-BR-3 | Lapatinib | 1 | uM | 9 | 312.50 | 200.50 | 207.00 | 350.25 | 0.5910 | 0.0404 |
| SK-BR-3 | Linsitinib | 10 | uM | 9 | 312.50 | 200.50 | 392.00 | 350.25 | 1.1192 | 1.3004 |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 330.00 | 350.25 | 0.9422 | 0.8573 |
| SK-BR-3 | Erlotinib | 10 | uM | 9 | 312.50 | 200.50 | 201.00 | 350.25 | 0.5739 | 0.0031 |
| SK-BR-3 | Linsitinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 338.00 | 350.25 | 0.9650 | 0.9135 |
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 439.00 | 350.25 | 1.2534 | 1.6479 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 9 | 312.50 | 200.50 | 257.00 | 350.25 | 0.7338 | 0.3614 |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 202.00 | 350.25 | 0.5767 | 0.0093 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 312.50 | 200.50 | 444.00 | 350.25 | 1.2677 | 1.6855 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 349.00 | 350.25 | 0.9964 | 0.9911 | |
| SK-BR-3 | 17-AAG | 0.0031623 | uM | 9 | 312.50 | 200.50 | 286.00 | 350.25 | 0.8166 | 0.5548 |
| SK-BR-3 | Linsitinib | 1 | uM | 9 | 312.50 | 200.50 | 292.00 | 350.25 | 0.8337 | 0.5954 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 364.00 | 350.25 | 1.0393 | 1.0980 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 389.00 | 350.25 | 1.1106 | 1.2785 | |
| SK-BR-3 | Linsitinib | 19.9526 | uM | 9 | 312.50 | 200.50 | 170.00 | 350.25 | 0.4854 | -0.1854 |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 329.00 | 350.25 | 0.9393 | 0.8504 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 372.00 | 350.25 | 1.0621 | 1.1555 |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 333.00 | 350.25 | 0.9508 | 0.8784 |
| SK-BR-3 | Linsitinib | 0.1 | uM | 9 | 312.50 | 200.50 | 404.00 | 350.25 | 1.1535 | 1.3882 |